Bio Protocol's Aubrai AI Token Targets $896K FDV Post-Ignition Sale, Tripling Initial Valuation

Bio Protocol has announced the commencement of the Ignition Sale for Aubrai, its inaugural BioAgent project, beginning this Monday. The 24-hour fixed-price sale, hosted on the Bio launchpad, sets Aubrai's Fully Diluted Valuation (FDV) at approximately $269,000, with an anticipated listing FDV of around $896,000 on an Automated Market Maker (AMM) immediately following the sale. This significant increase highlights the project's projected market entry value.

Participation in the Ignition Sale requires users to pledge BioXP and commit $BIO tokens to qualify for an allocation. "Your pledged BioXP determines your share of the sale," stated Bio Protocol in a recent tweet, emphasizing that the final allocation is calculated proportionally to an individual's BioXP contribution relative to the total pledged. The sale is not first-come, first-served, and allocations are capped at 0.5% of the total supply, or a maximum of 10,000 AUBRAI tokens per user.

Aubrai is positioned as a groundbreaking initiative leveraging artificial intelligence (AI) for bioinformatics and genetic data analysis within the decentralized science (DeSci) sector. Developed in collaboration with VitaDAO, Aubrai specifically aims to advance research in human longevity and anti-aging. The project's total token supply is set at 2 million, with 20% allocated for this initial sale, and the Token Generation Event (TGE) scheduled for August 25.

The launch of Aubrai has already positively impacted Bio Protocol's native BIO token, which has seen substantial price surges, including a 13-25% increase within 24 hours and over 111% growth in the past month, fueled by increasing whale accumulation. Bio Protocol has also strategically expanded its infrastructure to the Solana blockchain to enhance scalability and cross-chain compatibility. This move, alongside partnerships with entities like Sonnet BioTherapeutics, backed by major investment firms, underscores Bio Protocol's commitment to fostering innovation in decentralized biotech research.

Following the conclusion of the 24-hour Ignition Sale, AUBRAI is slated to commence open-market trading swiftly. This rapid transition from sale to public trading aims to provide immediate liquidity and accessibility for the new AI-driven DeSci token. The project represents a significant step for Bio Protocol as it continues to integrate advanced technologies into the decentralized scientific landscape.